Sanctuary Advisors LLC Increases Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Sanctuary Advisors LLC grew its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 6.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,836 shares of the biopharmaceutical company’s stock after acquiring an additional 1,109 shares during the quarter. Sanctuary Advisors LLC’s holdings in Dynavax Technologies were worth $245,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. US Bancorp DE increased its holdings in shares of Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,034 shares during the period. Capital Performance Advisors LLP purchased a new position in shares of Dynavax Technologies in the 3rd quarter valued at $45,000. GAMMA Investing LLC increased its holdings in shares of Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 1,457 shares during the period. Nisa Investment Advisors LLC increased its holdings in shares of Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 1,679 shares during the period. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in shares of Dynavax Technologies in the 4th quarter valued at $71,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Stock Up 2.6 %

Shares of DVAX stock opened at $13.88 on Wednesday. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $14.05. The stock’s fifty day moving average price is $12.93 and its 200 day moving average price is $12.16. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The company has a market cap of $1.72 billion, a price-to-earnings ratio of 77.11 and a beta of 1.32.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. The business had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. On average, research analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DVAX has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $31.00 price target on shares of Dynavax Technologies in a report on Friday, February 21st. The Goldman Sachs Group downgraded Dynavax Technologies from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. Finally, William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.